三维适形放疗联合诱导或同步培美曲塞治疗非小细胞肺癌的疗效分析  

Efficacy of concurrent or induction pemetrexed chemotherapy combined with 3D-radiotherapy for NSCLC

作　　者：尤圣勇 周江云[1] 彭康明[1] 

机构地区：[1]江苏省如皋市人民医院肿瘤科,如皋226500

出　　处：《中国肿瘤临床与康复》2013年第3期255-257,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨三维适形放疗联合培美曲塞和顺铂治疗非小细胞肺癌(NSCLC)同步和诱导方案的疗效。方法将56例NSCLC患者随机分为同步组(28例)和诱导组(28例)。均采用加速器6MV的X线三维适形放疗,总剂量60～70 Gy。诱导组放疗前行3个周期的培美曲塞(500mg/m2,第1天)和顺铂(20mg/m2,第1～3天)放疗诱导,放疗同时再给予化疗2个周期;同步组放疗当日给予培美曲塞(500mg/m2,第1天)和顺铂(75mg/m2,第1～3天)化疗3个周期。结果诱导组近期疗效显著高于同步组,造血系统毒性和胃肠道不良反应较轻。结论诱导方案能有效提高近期疗效,且不良反应较轻,是治疗NSCLC的较好方案。Objective The efficacy and toxicity of three-dimensional conformal radiotherapy（3D-CRT） combined with concurrent or induction pemetrexed chemotherapy to treat non-small cell lung cancer（NSCLC） was evaluated.Methods 56 patients were randomly divided into concurrent group and induction group.Induction group was given induction chemotherapy with pemetrexed（500mg/m2,d1） and cisplatin（20mg/m2,d1-3） every 3 weeks for 3 cycles followed by 3D-CRT（60~70 Gy） to continue chemotherapy for 2 cycles;concurren group received 3D-CRT plus concurrent chemotherapy with pemetrexed（500mg/m2,d1） and cisplatin（75mg/m2,d1-3）every 3 week for 3 cycles.Results The efficacy of induction group is significant better than concurrent group for NSCLC,and its toxicity is lower.Conclusions The effect is good using 3D-radiotherapy combined with induction pemetrexed and cisplatin to treat NSCLC.

关 键 词：非小细胞肺癌 三维适形放疗 诱导 培美曲塞 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]